Home
/ XOMA
/ Competitors

XOMA Competitors and Similar CompaniesClear all

XOMA's competitors and similar companies include Humanigen, Novartis, Pfizer and Moderna.

	XOMA XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics.	Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
Founding Date	Founding Date 1981	Founding Date 2000	Founding Date 1996	Founding Date 1849	Founding Date 2010
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Emeryville, US HQ	Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more
Employees	Employees 109% decrease	Employees 233% decrease	Employees 75,883	Employees 81,0008% decrease	Employees 5,8004% increase
Valuation ($)	Valuation ($) 353.7 m	Valuation ($) 4.3 m	Valuation ($) N/A	Valuation ($) 163.9 b	Valuation ($) 21.2 b
Financial
Revenue (est.)	Revenue (est.) $52.1m (FY, 2025)	Revenue (est.) $2.5m (FY, 2022)	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) $1.9b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $16.1b (FY, 2025)	Cost of goods $868m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $46.5b (FY, 2025)	Gross profit $1.1b (FY, 2025)
Net income	Net income $31.7m (FY, 2025)	Net income ($70.7m) (FY, 2022)	Net income $14b (FY, 2025)	Net income $7.8b (FY, 2025)	Net income ($2.8b) (FY, 2025)
Operating ⚠
Patent Applications	Patent Applications N/A	Patent Applications 17 (FY, 2017)	Patent Applications N/A	Patent Applications N/A	Patent Applications 430 (FY, 2021)
Patents (Foreign)	Patents (Foreign) N/A	Patents (Foreign) 42 (FY, 2017)	Patents (Foreign) N/A	Patents (Foreign) N/A	Patents (Foreign) 110 (FY, 2021)
Patents (US)	Patents (US) N/A	Patents (US) 18 (FY, 2017)	Patents (US) N/A	Patents (US) N/A	Patents (US) 170 (FY, 2021)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 5 (FY, 2024)	Registration Phase Products N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 131.7m	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised $ 1.8b